Drug Trial Radar · NCT07188844
An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
26
Actual
Start
Aug 28, 2025
Primary completion
Jul 16, 2026
Study completion Jul 16, 2026
Sponsor
- Lead sponsor
- Immunovant Sciences GmbHIndustry
- Sponsor type
- Industry
- First posted
- Sep 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label extension (OLE) study designed to evaluate the long-term safety and tolerability of batoclimab in participants with CIDP who have completed Study IMVT-1401-2401 (NCT05581199). In this study, participants will receive 340 mg of batoclimab subcutaneously (SC) once weekly (QW) for up to 52 weeks. Upon completion of the Week 52 or early termination (ET) Visit, participants will transition into the 4-week Follow-up Period, which concludes with a Follow-up Visit approximately 28 (± 7) days after the Week 52 or ET Visit.
Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
BatoclimabDrug
Batoclimab 340 mg SC QW
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants with Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and TEAEs Leading to Treatment DiscontinuationTime frame: Up to 52 weeks
Locations
30 sites in 11 countries. Site status is shown where the registry gives one.
Site Number - 1621
New Haven, Connecticut
Site Number - 1617
Ormond Beach, Florida
Site Number - 1611
Nicholasville, Kentucky
Site Number - 1610
Charlotte, North Carolina
Site Number - 1601
Austin, Texas
Site Number - 7750
Buenos Aires, Argentina
Site Number - 7752
San Miguel de Tucumán, Argentina
Site Number - 7753
Rosario, Santa Fe Province, Argentina
Site Number - 7751
Rosario, Santa Fe Province, Argentina
Site Number - 4680
Leuven, Vlaams Brabant, Belgium
Site Number - 9103
Brasília, Federal District, Brazil
Site Number - 9101
Curitiba, Paraná, Brazil
Site Number - 9100
Ribeirão Preto, São Paulo, Brazil
Site Number - 6702
Leipzig, Saxony, Germany
Site Number - 6347
Larissa, Greece
Site Number - 6341
Pátrai, Achaïa, Greece
Site Number - 6344
Athens, Attica, Greece
Site Number - 6305
Bologna, Emilia-Romagna, Italy
Site Number - 6309
Rome, Lazio, Italy
Site Number - 6307
Milan, Lombardy, Italy
Site Number - 3207
Poznan, Greater Poland Voivodeship, Poland
Site Number - 3208
Krakow, Lesser Poland Voivodeship, Poland
Site Number - 3209
Krakow, Lesser Poland Voivodeship, Poland
Site Number - 3210
Lublin, Lublin Voivodeship, Poland
Site Number - 3206
Lublin, Lublin Voivodeship, Poland
Site Number - 3201
Katowice, Silesian Voivodeship, Poland
Site Number - 8400
Constanța, Romania
Site Number - 8403
Timișoara, Timiș County, Romania
Site Number - 8501
Belgrade, Serbia
Site Number - 8603
Prešov, Slovakia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.